Evidence map›Paper›PMID 37242509›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Ricardo D Gonzalez, George W Small, Adrian J Green, Farida S Akhtari, Tammy M Havener, Julia C F Quintanilha, Amber B Cipriani, David M Reif, Howard L McLeod, Alison A Motsinger-Reif and 1 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Genomic Impacts of Biological Exposures.Journal of developmental biology · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Ricardo D GonzalezDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-2549-8138
George W SmallDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-7585-7258
Adrian J GreenDepartment of Biological Sciences, North Carolina State University, Raleigh, NC 27606, USA.ORCID 0000-0001-9429-1838
Farida S AkhtariBiostatistics and Computational Biology Branch, Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.
Tammy M HavenerStructural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Julia C F QuintanilhaClinical Development, Foundation Medicine, Boston, MA 02115, USA.ORCID 0000-0001-6908-4474
Amber B CiprianiDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-3596-0581
David M ReifPredictive Toxicology Branch, Division of Translational Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC 27709, USA.ORCID 0000-0001-7815-6767
Howard L McLeodCenter for Precision Medicine and Functional Genomics, Utah Tech University, St. George, UT 84770, USA.ORCID 0000-0002-9004-9232
Alison A Motsinger-ReifBiostatistics and Computational Biology Branch, Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.
Tim WiltshireDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
University of North Carolina at Chapel Hill · USNational Institute of Environmental Health Sciences · USFoundation Medicine (United States)North Carolina State University · USUtah Tech University · US

Funding

Statistical Genetics of Dose Response TraitsZIAES103336 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI MOTSINGER-REIF, ALISON · 2019 to 2024
$1.7M
NIEHS NIH HHS intramural funds
6 · The paper itself

Abstract

Temozolomide (TMZ) chemotherapy is an important tool in the treatment of glioma brain tumors. However, variable patient response and chemo-resistance remain exceptionally challenging. Our previous genome-wide association study (GWAS) identified a suggestively significant association of SNP rs4470517 in the

Indexed as

chemotherapydrug responsegene expressiongliomaGWASknockdownoverexpressionpharmacogenomicsresistanceRYKsensitivitytemozolomide

Identifiers

PMID37242509
PMCPMC10220703
OpenAlexW4378515543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.